Neisseria meningitidis

Human medicines European public assessment report (EPAR): Epysqli, Date of authorisation: 26/05/2023, Revision: 1, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Epysqli, Date of authorisation: 26/05/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Epysqli, Date of authorisation: 26/05/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Zilbrysq, Zilucoplan, Date of authorisation: 01/12/2023, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Zilbrysq, Zilucoplan, Date of authorisation: 01/12/2023, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zilbrysq, Zilucoplan, Date of authorisation: 01/12/2023, Status: Authorised

Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives

Retrieved on: 
Monday, November 27, 2023

SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We thank the Canadian Government for their recognition of the significant potential of Recce’s New Class of Anti-infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • In July 2023, the Company received an AUD $98,428 R&D Rebate from the Canadian Government, under the Scientific Research & Experimental Development (SR&ED) Tax Incentive program.
  • The program is administered by the Canada Revenue Agency and is aimed at incentivizing businesses to conduct R&D in Canada, encouraging innovation and technological advancements.

AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients

Retrieved on: 
Friday, August 25, 2023

To help protect access to medicines for cancer and rare disease patients, AstraZeneca today has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act (IRA).

Key Points: 
  • To help protect access to medicines for cancer and rare disease patients, AstraZeneca today has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act (IRA).
  • Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: “Rare disease and cancer patients depend upon high-risk, low-probability drug development that takes many years to develop and aims for cure.
  • One example is LYNPARZA® (olaparib), a small-molecule cancer medicine approved in 2014 in the US for a small group of late-line ovarian cancer patients.
  • Additional trials added small groups of breast and pancreatic cancer patients, with the most recent indication in prostate cancer approved just this year – nine years later.

Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease

Retrieved on: 
Friday, August 18, 2023

TARRYTOWN, N.Y., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has approved Veopoz™ (pozelimab-bbfg) for the treatment of adult and pediatric patients 1 year of age and older with CHAPLE disease, also known as CD55-deficient protein-losing enteropathy. Veopoz is the first and only treatment indicated specifically for CHAPLE. With the approval of Veopoz, the pre-approval inspection issues related to the aflibercept 8 mg BLA have been addressed. FDA action on the aflibercept 8 mg BLA is expected in the next few weeks.

Key Points: 
  • With the approval of Veopoz, the pre-approval inspection issues related to the aflibercept 8 mg BLA have been addressed.
  • FDA action on the aflibercept 8 mg BLA is expected in the next few weeks.
  • Veopoz was reviewed under Priority Review, and the Company received a Rare Pediatric Disease Priority Review voucher upon approval.
  • Veopoz was previously granted Rare Pediatric Disease designation, Orphan Disease designation and Fast Track designation.

Recce Pharmaceuticals Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
Friday, August 4, 2023

SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We are thrilled to receive this new family of intellectual property, granted by the Australian Patent Office, with further market monopolies reinforcing opportunities among a significant range of bacterial and viral pathogens,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Viral infections may be caused by a range of viruses, such as coated viruses (e.g., lipid-coated viruses), including herpes, human immunodeficiency virus (HIV), cytomegalovirus, and influenza.
  • Other examples include Influenza A, Ross River virus, and coronavirus, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Global Adult Vaccine Market Projected to Reach $27.65 Billion by 2028 with a Strong CAGR of 6.01% During 2023-2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 28, 2023

The global adult vaccine market is expected to witness substantial growth, reaching a projected value of US$ 27.65 Billion by 2028, with a strong compound annual growth rate (CAGR) of 6.01% during 2022-2028.

Key Points: 
  • The global adult vaccine market is expected to witness substantial growth, reaching a projected value of US$ 27.65 Billion by 2028, with a strong compound annual growth rate (CAGR) of 6.01% during 2022-2028.
  • Furthermore, government partnerships with biotechnology and pharmaceutical firms to develop new vaccines are contributing to the growth of the adult vaccine market.
  • By Vaccine Type, the adult vaccine market is divided into Influenza, HPV, Zoster, MMR, Pneumococcal, Meningococcal, Hepatitis, Tdap, travel and misc, and varicella.
  • The Adult Vaccine Market is categorized by Vaccinated Population into Influenza, HPV, Zoster, MMR, Meningococcal, Pneumococcal, Hepatitis, Tdap, and Varicella.

CANbridge Reports Positive Preliminary Data in the Omoprubart (CAN106) Phase 1b Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH) in China

Retrieved on: 
Monday, June 26, 2023

The goals of the study are to assess safety, pharmacokinetics, pharmacodynamics and efficacy in subjects with PNH.

Key Points: 
  • The goals of the study are to assess safety, pharmacokinetics, pharmacodynamics and efficacy in subjects with PNH.
  • Data from the two lower dose cohorts was reviewed through 26 weeks, while data from the highest dose cohort was reviewed through 13 weeks, the latest timepoint.
  • CANbridge plans to advance Omoprubart to a pivotal trial in PNH in China, where there are no approved long-acting PNH treatments.
  • Based on the strength of these data, we plan to advance omoprubart to a pivotal trial in PNH in China and will meet shortly with the CDE to discuss our next steps.

NJ Students Announced as Winners of 11th Annual Adolescent Immunization Awareness Contest

Retrieved on: 
Friday, May 12, 2023

NEWARK, N.J., May 12, 2023 /PRNewswire/ -- The Partnership for Maternal and Child Health of Northern New Jersey, in collaboration with the New Jersey Department of Health, has announced the winners of the 11th annual Protect Me With 3+ adolescent immunization awareness poster and video contest.

Key Points: 
  • NEWARK, N.J., May 12, 2023 /PRNewswire/ -- The Partnership for Maternal and Child Health of Northern New Jersey, in collaboration with the New Jersey Department of Health, has announced the winners of the 11th annual Protect Me With 3+ adolescent immunization awareness poster and video contest.
  • The artistic submissions we received showcase the talent of New Jersey's middle and high school students.
  • "We're so grateful for the opportunity to partner with the New Jersey Department of Health again on this fun, youthful contest.
  • "This contest empowers students to advocate for their health and promotes the importance of immunizations across the lifespan."

Recce Pharmaceuticals to be Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
Tuesday, April 11, 2023

SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We would like to thank the Australian Patent Office for this notification of intent, which further validates the potential of our new class of anti-infectives to help patients with a broad range of bacterial and viral infections,” said James Graham, Chief Executive Officer of Recce Pharmaceutical.
  • Viral infections that may be caused by a range of viruses, such as coated viruses (e.g., lipid-coated viruses), include herpes, human immunodeficiency virus (HIV), cytomegalovirus, and influenza.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome.